Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Atazanavir / cobicistat (Evotaz®) in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir. |
|||
|
|||
Medicine details |
|||
| Medicine name | atazanavir / cobicistat (Evotaz®) | ||
| Formulation | 300 mg/150 mg film-coated tablet | ||
| Reference number | 2629 | ||
| Indication | Treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir |
||
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 4115 | ||
| NMG meeting date | 04/11/2015 | ||
| AWMSG meeting date | 09/12/2015 | ||
| Ratification by Welsh Government | 06/01/2016 | ||
| Date of issue | 11/01/2016 | ||
| Date of last review | 20/03/2019 | ||